PR Newswire
NEW YORK, July 28, 2014
NEW YORK, July 28, 2014 /PRNewswire/ -- The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) ("Salix Pharmaceuticals") in connection with the sale of the Company to a subsidiary of Cosmo Pharmaceuticals S.p.A.
Click here to learn about the case: http://docs.wongesq.com/SLXP-Info-Request-Form-295. There is no cost or obligation to you.
Under the terms of the transaction, Salix Pharmaceuticals shareholders will receive one share of the post-merger entity for each share of Salix Pharmaceuticals they own. The investigation concerns whether the Salix Pharmaceuticals Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Cosmo Pharmaceuticals S.p.A. is underpaying for Salix Pharmaceuticals shares.
If you own common stock in Salix Pharmaceuticals and wish to obtain additional information, please contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/SLXP-Info-Request-Form-295.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE The Law Offices of Vincent Wong
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.